UC San Diego VC Partner Osage Invests in Antiva
May 18, 2017
Antiva Biosciences, a spinout of UC San Diego, closed a $22M Series C financing in March. Antiva is a clinical stage biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by Human Papilloma Virus (HPV) infection. Osage University Partners, a venture capital firm partnered with UC San Diego that invests exclusively in startups that are commercializing university research, invested in this round.
